Meenal Kheterpal

Positions:

Assistant Professor of Dermatology

Dermatology
School of Medicine

Member of the Duke Cancer Institute

Duke Cancer Institute
School of Medicine

Education:

M.D. 2013

University of Michigan, Ann Arbor

Grants:

A Multicenter, Randomized, Double-blind, Vehicle-controlled, Phase 3 Efficacy and Safety Study of Patidegib Topical Gel, 2%, for the Reduction of Disease Burden of Persistently Developing Basal Cell C

Administered By
Dermatology
Awarded By
PellePharm
Role
Principal Investigator
Start Date
End Date

Qualification of the Methodology to Identify and Measure Basal Cell Carcinomas (BCCs) on the face of patients with Basal Cell Nevus Syndrome (Gorlin Syndrome) or Sporadic BCCs

Administered By
Dermatology
Awarded By
PellePharm
Role
Principal Investigator
Start Date
End Date

A Phase 1 Study of Pre-Operative Cemiplimab (REGN2810), Administered Intralesionally, for Patients with Recurrent Cutaneous Squamous Cell Carcinoma (CSCC)

Administered By
Duke Cancer Institute
Awarded By
Regeneron Pharmaceuticals, Inc.
Role
Principal Investigator
Start Date
End Date

Pelle-926-301E: A Phase 3, Multicenter, Open-Label Extension Study of Patidegib Topical Gel, 2% in Subjects with Gorlin Syndrome (Basal Cell Nevus Syndrome)

Administered By
Dermatology
Awarded By
PellePharm
Role
Principal Investigator
Start Date
End Date

A Multicenter, Randomized, Double blind, Vehicle-controlled, Phase 2 Efficacy and Safety Study of Patidegib Topical Gel, 2%, for the Reduction of Disease Burden of Persistently Developing Basal Cell C

Administered By
Dermatology
Awarded By
PellePharm
Role
Principal Investigator
Start Date
End Date

Publications:

Apremilast for the off-label treatment of lichenoid and interface dermatoses.

Authors
Ravichandran, S; Kheterpal, MK
MLA Citation
Ravichandran, Surya, and Meenal K. Kheterpal. “Apremilast for the off-label treatment of lichenoid and interface dermatoses.J Am Acad Dermatol, June 2020. Pubmed, doi:10.1016/j.jaad.2020.05.112.
URI
https://scholars.duke.edu/individual/pub1447412
PMID
32497705
Source
pubmed
Published In
Journal of the American Academy of Dermatology
Published Date
DOI
10.1016/j.jaad.2020.05.112

Radiation therapy for primary cutaneous γδ T-cell lymphoma: Case report and literature review.

Authors
Kelsey, CR; Wang, E; Stefanovic, A; Kheterpal, M
MLA Citation
Kelsey, Chris R., et al. “Radiation therapy for primary cutaneous γδ T-cell lymphoma: Case report and literature review.Jaad Case Rep, vol. 5, no. 7, July 2019, pp. 582–86. Pubmed, doi:10.1016/j.jdcr.2019.05.002.
URI
https://scholars.duke.edu/individual/pub1395978
PMID
31312707
Source
pubmed
Published In
Jaad Case Reports
Volume
5
Published Date
Start Page
582
End Page
586
DOI
10.1016/j.jdcr.2019.05.002

Resolution of Pembrolizumab-Associated Steroid-Refractory Lichenoid Dermatitis with Cyclosporine.

Checkpoint inhibitors such as pembrolizumab, an anti-PD-1 monoclonal antibody, are a promising new category of oncological therapeutics, associated with a higher risk of immune-related adverse events including dermatological, autoimmune and endocrine sequelae. Here, we present a case of a woman 76 years of age with stage IV lung adenocarcinoma who developed a severe and steroid-refractory lichenoid dermatitis associated with pruritus on pembrolizumab. This eruption resolved completely with a short course of oral cyclosporine. Cyclosporine is a promising and effective treatment option for checkpoint inhibitor-related severe cutaneous eruptions.
Authors
Fixsen, E; Patel, J; Selim, MA; Kheterpal, M
MLA Citation
Fixsen, Emma, et al. “Resolution of Pembrolizumab-Associated Steroid-Refractory Lichenoid Dermatitis with Cyclosporine.Oncologist, vol. 24, no. 3, Mar. 2019, pp. e103–05. Pubmed, doi:10.1634/theoncologist.2018-0531.
URI
https://scholars.duke.edu/individual/pub1364799
PMID
30617087
Source
pubmed
Published In
Oncologist
Volume
24
Published Date
Start Page
e103
End Page
e105
DOI
10.1634/theoncologist.2018-0531

Role of imaging in low-grade cutaneous B-cell lymphoma presenting in the skin.

BACKGROUND: Whole-body imaging is the current standard of care for staging all patients presenting with skin lesions of B-cell lymphomas (BCLs), regardless of skin disease extent; however, supporting data are lacking. OBJECTIVE: To determine the clinical utility of imaging in the detection of systemic involvement in low-grade cutaneous BCLs in the skin. METHODS: Retrospective cohort analysis of patients presenting with cutaneous lesions of BCLs at Memorial Sloan Kettering Cancer Center and Stanford University during 1997-2016. RESULTS: At initial staging, of the 522 patients, extracutaneous disease was noted in 3.6% and 8.8% of patients with marginal zone lymphoma (MZL, n = 306) and follicle center lymphoma (FCL, n = 216) histology, respectively. In patients with systemic involvement, imaging alone identified 81.8% (9/11) of MZL cases and 89.4% of follicular lymphoma cases. In primary cutaneous MZL, 1.7% of patients subsequently had extracutaneous involvement (median follow-up 45 months), and in primary cutaneous FCL. 3.0% subsequently had extracutaneous involvement (median follow-up 47 months). LIMITATIONS: This was a retrospective study. CONCLUSION: Imaging is effective at identifying patients with systemic involvement in indolent BCLs present in the skin; however, incidence is low. After negative initial staging, primary cutaneous MZL patients may be followed clinically without routine imaging.
Authors
Kheterpal, MK; Dai, J; Geller, S; Pulitzer, M; Ni, A; Myskowski, PL; Moskowitz, A; Kim, J; Hong, EK; Fong, S; Hoppe, RT; Kim, YH; Horwitz, SM
MLA Citation
Kheterpal, Meenal K., et al. “Role of imaging in low-grade cutaneous B-cell lymphoma presenting in the skin.J Am Acad Dermatol, vol. 81, no. 4, Oct. 2019, pp. 970–76. Pubmed, doi:10.1016/j.jaad.2019.01.037.
URI
https://scholars.duke.edu/individual/pub1368762
PMID
30703460
Source
pubmed
Published In
Journal of the American Academy of Dermatology
Volume
81
Published Date
Start Page
970
End Page
976
DOI
10.1016/j.jaad.2019.01.037

The impact of dermatology in premier medicine journals.

In the past 15 years, research in dermatology has significantly increased. Dermatology-related contributions in premier medical journals such as The New England Journal of Medicine (NEJM) and The Journal of the American Medical Association (JAMA) are the representation of our field in the medical world. To analyze this representation, incidence of dermatology-related contributions in NEJM and JAMA during 3 separate years (during a 15-year period) was calculated.
Authors
Kheterpal, MK; Ellis, CN
MLA Citation
Kheterpal, Meenal K., and Charles N. Ellis. “The impact of dermatology in premier medicine journals.Skinmed, vol. 9, no. 5, Sept. 2011, pp. 288–92.
URI
https://scholars.duke.edu/individual/pub1285093
PMID
22165043
Source
pubmed
Published In
Skinmed
Volume
9
Published Date
Start Page
288
End Page
292